Sera Prognostics, Inc. (SERA)
Automate Your Wheel Strategy on SERA
With Tiblio's Option Bot, you can configure your own wheel strategy including SERA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SERA
- Rev/Share 0.0027
- Book/Share 2.2585
- PB 0.7262
- Debt/Equity 0.0009
- CurrentRatio 2.0206
- ROIC -0.3878
- MktCap 60196200.0
- FreeCF/Share -0.6464
- PFCF -2.219
- PE -2.0864
- Debt/Assets 0.0007
- DivYield 0
- ROE -0.5135
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago.
Read More
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth Quarter Fiscal Year 2024 Results. At this time, all participants are in listen-only mode.
Read More
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m.
Read More
Sera Prognostics Announces Pricing of $50 Million Public Offering
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which …
Read More
Sera Prognostics Announces Proposed Public Offering
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount …
Read More
About Sera Prognostics, Inc. (SERA)
- IPO Date 2021-07-15
- Website https://seraprognostics.com
- Industry Medical - Diagnostics & Research
- CEO Ms. Evguenia Lindgardt M.B.A.
- Employees 63